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SUMMARY
Intestinal epithelial stem cell (IESC) fate is promoted by two major transcriptional regulators, the TCF4/b-catenin complex and ASCL2,
which drive expression of IESC-specific factors, including Lgr5, Ephb2, and Rnf43. Canonical Wnt signaling via TCF4/b-catenin directly
transactivatesAscl2, which in turn auto-regulates its own expression. Conversely, Let-7microRNAs antagonize the IESC lineage by repres-
sing specificmRNA targets. Here, we identify the zinc finger transcription factor PLAGL2 as a Let-7 target that regulates IESC fate. PLAGL2
drives an IESC expression signature, activatesWnt gene expression, and enhances a TCF/LEF reporter in intestinal organoids. In parallel,
via cell-autonomous mechanisms, PLAGL2 is required for lineage clonal expansion and directly enhances expression of ASCL2. PLAGL2
also supports enteroid growth and survival in the context ofWnt ligand depletion. PLAGL2 expression is strongly associatedwith an IESC
signature in colorectal cancer and may be responsible for contributing to the aberrant activation of an immature phenotype.
INTRODUCTION
Intestinal epithelial stem cells (IESCs) reside in intestinal
crypts and give rise to all endodermally derived lineages
of the epithelium. The IESC consists of at least two distinct
populations. The first is actively dividing, expresses high
levels of the GPCR class A receptor LGR5 (Barker et al.,
2007), is located at the base of intestinal crypts (Barker
et al., 2007), and is highly dependent on Wnt signaling
(de Lau et al., 2011; Yan et al., 2017). A second quiescent
IESC is located near the base of crypts (Li et al., 2014; San-
giorgi and Capecchi, 2008; Takeda et al., 2011; Tian et al.,
2011; Yan et al., 2012) and has properties of a secretory pro-
genitor (Buczacki et al., 2013). Wnt signaling is necessary
for the establishment of IESCs in post-natal intestinal
development in mice (Korinek et al., 1998; Pinto et al.,
2003). Ascl2 is also required for IESC specification (van
der Flier et al., 2009), and maintenance of IESCs, through
cooperation with TCF4 and b-catenin to transactivate
genes such as Lgr5 and Sox9 (Schuijers et al., 2015).
Let-7 microRNAs (miRNAs) are key regulators of cellular
proliferation and differentiation in a variety of contexts
and organisms, from C. elegans (Lee and Ambros, 2001;
Slack et al., 2000) to humans. Let-7 frequently acts to
repress stem cell fate or proliferation, as observed in fetal
hematopoietic stem cells (Copley et al., 2013; Oshima
et al., 2016; Rowe et al., 2016), neural stem cells (Rybak
et al., 2008; Zhao et al., 2010), primordial germ cells
(Tran et al., 2016; West et al., 2009), and IECs (Madison
et al., 2015). The RNA-binding proteins, LIN28A and
LIN28B, directly inhibit Let-7 in stem and progenitor cells
(Hagan et al., 2009; Rahkonen et al., 2016). LIN28 proteins
block Let-7 miRNA function by preventing Let-7 post-tran-
scriptional maturation (Hagan et al., 2009; Heo et al., 2008;
Piskounova et al., 2008; Viswanathan et al., 2008). Deple-
tion of Let-7 miRNAs is frequently observed in cancer,
and directly contributes to epithelial transformation in
colorectal cancer (CRC) (King et al., 2011), while depletion
in the mouse intestine via transgenic LIN28A/B expression
drives the formation of spontaneous, aggressive adenocar-
cinomas (Madison et al., 2013; Tu et al., 2015). LIN28 pro-
teins are expressed in the developing mouse gut, but only
LIN28B is detectable in the adult intestine, exhibiting nu-
clear localization in the epithelial crypt compartment
(Madison et al., 2013). In mouse models, overexpression
of LIN28B in the intestinal epithelium augments the
expression of stem cellmarkers and enhances colony-form-
ing potential of small intestinal organoids (enteroids)
(Madison et al., 2013, 2015). Consistent with this, levels
of Let-7a and Let-7b miRNAs are inversely proportional to
mRNA levels of LGR5 and EPHB2 in human CRC, which
represent classical IESC markers (Madison et al., 2015).
Further examination of Let-7 targets that mediate these ef-
fects revealed that the canonical Let-7 target Hmga2 is
required for LIN28B-driven enhancement of colony-form-
ing potential in mouse enteroids (Madison et al., 2015).
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However, HMGA2 overexpression in mouse enteroids does
not alter the abundance of any IESCmarker and only drives
a modest enhancement of colony-forming potential (Mad-
ison et al., 2015).
Here we identify PLAGL2 as a Let-7 target that is strongly
associated with an IESC signature. PLAGL2 encodes a zinc
finger transcription factor found within a genomic region
at 20q11.21 that is frequently amplified in CRC (Carvalho
et al., 2009; He et al., 2003; Hermsen et al., 2002). PLAGL2
is expressed at high levels in various tissues of the devel-
oping fetus and placenta and plays a critical role in late in-
testinal epithelial differentiation (Van Dyck et al., 2007).
We have reported that PLAGL2 levels are enhanced by
overexpression of LIN28B in the intestinal epithelium
(Madison et al., 2015), consistent with its inverse correla-
tion with Let-7 levels in CRC (Madison et al., 2015). We
find here that PLAGL2 is a direct Let-7 target that drives
stem cell fate and is required for stem cell function in orga-
noids. One mechanism involves the direct downstream
activation of the IESC lineage factor ASCL2, where we
find that PLAGL2 binds to a conserved consensus sequence
in the proximal ASCL2 promoter.
RESULTS
Interrogation of TCGACRCRNA sequencing (RNA-seq) da-
tasets reveals that PLAGL2 expression correlates highly
with multiple lineage factors specific for––or highly en-
riched in—CBC IESCs (Munoz et al., 2012; Sato et al.,
2011), including ASCL2, EPHB2, NOTCH1, RNF43, and
MYC (Figure S1A). Among patient-derived CRC xenograft
lines (Uronis et al., 2012), this trend is also evident, with
significant correlation between PLAGL2 and ASCL2,
RNF43, and NOTCH1 (Figure S1B). In a dataset of human
colorectal adenomas (Sabates-Bellver et al., 2007), we also
observe the co-expression of PLAGL2 with CBC IESC
markers, which are coordinately upregulated together in
adenomas relative to normal tissue (Figure S1C).
We used human intestinal organoids to examine the rela-
tionship of LIN28B-Let-7, PLAGL2, and effects on stem
cells. As expected, LIN28B overexpression in organoids en-
hances colony-forming potential (Figure 1A). PLAGL2,
along with the validated Let-7 target, HMGA2, is upregu-
lated in a pattern similar to ASCL2 in these organoids (Fig-
ure 1B). PLAGL2 upregulation in the intestinal epithelium,
downstream of LIN28B, is also observed in our mouse
models of LIN28B overexpression (Madison et al., 2015).
Thus, PLAGL2 activation is a downstream feature of
LIN28B-mediated enhancement of stem cell activity.
To definitively classify PLAGL2 as a Let-7 target, we pur-
sued validation in in vitro models. Transfection of a Let-7b
miRNA mimic into DLD1 CRC cells caused a significant
depletion of PLAGL2mRNA (Figure 1C).We also developed
a heterologous reporter system with destabilized GFP and
RFP proteins for real-time evaluation of Let-7 miRNA
repression (Figure 1D). In the context of a synthetic array
of seven Let-7 target sites, reporter activity is repressed
60%–70% by Let-7a (Figure 1E). Likewise, assays of the
PLAGL2 30 UTR reveal a 40% decrease of reporter activity
by Let-7a (Figure 1F) that is completely abrogated by muta-
tions in each of two Let-7 recognition sequences in the
PLAGL2 30 UTR (Figure 1F). Thus, this supports our hypoth-
esis that PLAGL2 is directly repressed by Let-7.
To model the aberrant upregulation of PLAGL2 that
is likely within the context of Let-7 loss, LIN28B de-repres-
sion, or 20q11.21 amplification, we generated murine
enteroids constitutively overexpressing hemagglutinin-
tagged PLAGL2. This yieldedmodest expression of PLAGL2
protein in two separate clones (Figure 2A). PLAGL2 expres-
sion causes amarked increase in cyst-like enteroids (Figures
2B–2D). PLAGL2-expressing enteroids also exhibit a dose-
dependent increase in colony-forming potential (Figures
2E and 2F). Similar effects were observed upon PLAGL2
expression in human colonic organoids, with an augmen-
tation of colony-forming potential (Figure 2G). In human
organoids, we observe enhancement of proliferation as
measured by 5-ethynyl-20-deoxyuridine incorporation
(Figures 2H–2J). This effect is only evident when organoids
are cultured in medium lacking Wnt3a. Inactivation of
Plagl2 in mouse enteroids with CRISPR/Cas revealed de-
fects in colony-forming potential of mutants (Figures 2K–
2M). However, no significant changes in enteroid growth
were observed (Figure 2N). To gain insight into the cell-
autonomous function of PLAGL2, we performed lineage-
tracing experiments in enteroids stably expressing the
Cas9D10A nuclease followed by stable transfection with a
transposon constitutively expressing both GFP and gRNAs
against Plagl2. Following transfection, the majority of sur-
viving organoids do not contain GFP-positive transfected
cells. However, a minority (2%) show evidence of clonal
expansion of GFP-positive clones, while targeted inactiva-
tion of Plagl2 causes a reduction in these lineage-tracing
events (Figure 2O), as observed over 7 days following the
transfection (Figure 2P). Thus, PLAGL2 supports the stem
cell lineage in a cell-autonomous manner in enteroids.
To gain insight into pathways operating downstream
of PLAGL2 we performed RNA-seq in two mouse enter-
oid clones overexpressing PLAGL2 (Figure 3A). Because
PLAGL2 appears to drive stem cell fate in enteroids, we per-
formed gene set enrichment analysis (GSEA) (Subramanian
et al., 2005) on PLAGL2-induced mRNAs in comparison
with an expression dataset for GFP-sorted CBC IESCs
from Lgr5-EGFP mice (Barker et al., 2007; Munoz et al.,
2012). This reveals significant enrichment (Figure 3B), indi-
cating that PLAGL2 drives a CBC stem cell expression
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signature. This was true for both PLAGL2 clone no. 1 (false
discovery rate [FDR] q < 0.001) and no. 2 (FDR q < 0.02). An
unbiased GSEA query of all molecular function gene
ontology gene sets reveals that PLAGL2-upregulated tran-
scripts are enriched for genes associated with Frizzled bind-
ing (Figure 3C), both for PLAGL2 clone no. 1 (FDR q =
0.164) and no. 2 (FDR q = 0.317). Further examination re-
veals several Wnt ligands (Wnt9b, Wnt4, Wnt10a, and
Wnt5a) are upregulated by PLAGL2 (Figure 3D), which
was validated by RT-PCR (Figure 3E). Decreased expression
of Wnt target genes, Cd44 and Axin2, in Plagl2 null enter-
oids also supported a positive role for PLAGL2 in driving ca-
nonical Wnt signaling (Figure 3F).
To gauge effects on Wnt we generated enteroids with a
stable TCF/LEF reporter transgene driving expression of nu-
clear localized tdTomato (TOP-tdT, Figure 3G), which ex-
hibited the expected sensitivity to manipulation of Wnt
signaling with GSK3b and Porcupine inhibitors (Figures
3H and 3I). Transgenic co-expression of PLAGL2 in enter-
oids caused a marked increase in the number of TOP-tdT-
positive cells (Figures 3J–3O), although upregulation of
TOP-tdT reporter activity within each individual cell ap-
peared variable (Figure 3P) and did not correlate with levels
of overexpressed PLAGL2 mRNA (Figure 3Q). To better
measure possible effects of secreted signals on TOP-tdT
reporter activity, GFP-labeled wild-type (WT) TOP-tdT
enteroids were co-cultured with PLAGL2-expressing enter-
oids (Figure 3R). Reporter activity in GFP-labeled co-
cultured enteroids was enhanced by these PLAGL2 enter-
oids (Figure 3S). Consistent with an enhancement of Wnt
signaling, colony-forming potential was augmented in
WT ROSA26mTmG enteroids co-cultured with PLAGL2 en-
teroids (Figure 3T). Thus, PLAGL2 drives modest enhance-
ment of canonical Wnt signaling, non-cell-autonomously.
To determine if Wnt signaling is the primary underlying
driver of the PLAGL2 phenotype in enteroids, we treated
Figure 1. PLAGL2 Is Directly Repressed by Let-7 miRNAs
(A) Human organoids were plated as single cells in Matrigel for a colony-forming assay, in quadruplicate. Colonies were counted after
7 days in culture.
(B) Expression levels of PLAGL2, HMGA2, and ASCL2 were assayed in two human organoid clones constitutively expressing LIN28B
(LIN28B O/E).
(C) Transient transfection of DLD1 cells with a Let-7b miRNA mimic causes the depletion of endogenous PLAGL2 mRNA, as assayed by
RT-PCR 72 hr after transfection.
(D) Schematic of a transposon miRNA reporter vector for assaying effects of Let-7a on the PLAGL2 30 UTR.
(E) Validation of the miRNA reporter vector containing a synthetic Let-7 target with seven repeats of the Let-7 target seed sequence.
(F) The miRNA reporter vector containing the PLAGL2 30 UTR and a non-specific miRNA or Let-7a. Mutation (Mut) of both Let-7 target seed
sequences in the PLAGL2 30 UTR renders the reporter resistant to Let-7.
Student’s one-tailed t test was performed to evaluate significance between means of replicates, where *p < 0.05 and **p < 0.01.
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Figure 2. PLAGL2 Drives Stem Cell Potential in Enteroids
(A) Mouse enteroids stably overexpressing (O/E) hemagglutinin-tagged PLAGL2 or GFP were evaluated by immunoblot.
(B–D) GFP-expressing enteroids appeared morphologically similar to un-transfected parental enteroids (not shown) (B), whereas PLAGL2
O/E enteroids (clone no. 2) frequently formed large cysts (C), quantified in (D).
(E and F) Stitched representative microscopic images of colony-forming assay (CFA) of PLAGL2 O/E mouse enteroids, performed in
quadruplicate (E), which are quantified in (F).
(G) Quantification of colony-forming assay of PLAGL2-expressing human colonoids.
(H–J) 5-Ethynyl-20-deoxyuridine (EdU) incorporation in human colonoids as quantified in sections (H), with representative images for
empty vector (I) and PLAGL2-expressing human colonoids (J).
(K–M) Representative images of CFA of Plagl2 mutant mouse ileum enteroids, performed in quadruplicate (K), which are quantified in (L),
while Plagl2 mutant mouse jejunum enteroids are quantified in (M).
(N) Plagl2 mutant mouse enteroid size over 6 days of culture.
(legend continued on next page)
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cultures with IWP-2, a small molecule that blocks Wnt pal-
mitoylation and secretion through inhibition of Porcupine
(Chen et al., 2009). After 5–7 days of IWP-2 treatment
the vast majority of control (GFP-expressing) enteroids
die, while surviving enteroids eventually regress (Figure 4A).
However, many PLAGL2-expressing enteroids survive
IWP-2 treatment, either as cysts or budding structures (Fig-
ure 4B), which is never observed in controls (Figure 4C). To
further parse Wnt dependency, PLAGL2 enteroids with the
TOP-tdTreporter were treatedwith IWP-2 and closelymoni-
tored for reporter activity (Figures 4D–4F).DespiteWnt inhi-
bition, PLAGL2 enteroidsmaintain higher expression levels
of the IESC lineage markers Ascl2 and Lgr5 (Figure 4G), but
do not drive higher expression of other Wnt target genes
(Figure 4H). To see if PLAGL2 maintains stem cell potential
in the face of Wnt inhibition, we continued IWP-2 treat-
ment of enteroids (from Figures 4E and 4F) for 2 additional
days, confirmed complete loss of the TOP-tdT reporter in
each enteroid, and then re-plated remaining enteroids in
fresh medium lacking IWP-2. PLAGL2-expressing enteroids
yielded significantly more numerous new colonies, relative
to the initial number of enteroids (Figures 4I–4K). Thus,
PLAGL2 can drive intestinal epithelial growth and support
stem cell potential despite severe Wnt depletion.
Oddly, despite the apparent augmentation of Wnt
signaling by PLAGL2, TCF4/b-catenin target genes are not
induced by PLAGL2 overexpression (Figure 5A). However,
RNA-seq did reveal that ASCL2 target genes (as previously
described by Schuijers et al., 2015) were modestly induced,
in a dose-dependent manner, in PLAGL2-expressing enter-
oids (Figure 5A). RT-PCR for canonical Wnt target genes
Axin2 and Cd44 confirmed no increase of these transcripts
(Figure 5B). Expression analysis in both mouse (Figure 5C)
and human (Figure 5D) organoids confirmed that PLAGL2
augments expression of ASCL2, in a dose-dependent
manner. Using a gene set of ASCL2-induced transcripts
(Schuijers et al., 2015) we compared PLAGL2-modulated
transcripts using GSEA, which reveals enrichment of an
ASCL2 signature in PLAGL2-upregulated genes (Figure 5E).
Decreased expression of Ascl2 and the ASCL2 target, Lgr5,
in Plagl2 null enteroids also suggests a positive role for
PLAGL2 in supporting ASCL2 expression (Figure 5F).
Although ASCL2 is a TCF4/b-catenin target gene (Gia-
kountis et al., 2016; Schuijers et al., 2015) that could be
activated by increased levels of Wnt ligands, we investi-
gated a possible Wnt-independent relationship between
PLAGL2 and ASCL2. We looked first at available RNA-seq
data for CRC tumors, which frequently possess Wnt-acti-
vating mutations. RNA-seq data from CRC tumors were
parsed according to common Wnt-activating mutations
(truncating mutations in APC or AXIN2, or missense muta-
tions in CTNNB1). This revealed a strong relationship be-
tween PLAGL2 and ASCL2 expression, regardless of these
hallmarks of aberrant canonical Wnt pathway activation
(Figure 5G). We then examined this relationship in a
CRC tumor cell line, DLD1, which has inactivating muta-
tions in APC. Inactivation of the endogenous PLAGL2
gene in DLD1 CRC cells (Figure S2) causes a stepwise loss
of ASCL2 mRNA (Figure 5H), suggesting dependency on
PLAGL2, despite constitutive Wnt pathway activation in
these cells. Thus, PLAGL2 is a necessary component of
the regulatory mechanisms operating upstream of ASCL2.
We next examined whether the cell-autonomous defect
in lineage tracing following mutagenesis of Plagl2 (Fig-
ure 2O) could be rescued by ASCL2. In enteroids trans-
fected with the stable gRNA transposon, we co-transfected
an ASCL2-expressing transposon. ASCL2 rescued the line-
age-tracing defect in Plagl2-mutated enteroids (Figure 5I).
Both T7E1 assays (Figure 5J) and Illumina-based genotyp-
ing for the targeted region of Plagl2 (Figure 5K) revealed
similar levels of mutagenesis in both populations, but not
enteroids targeted with a non-specific gRNA.
To investigate the importanceof PLAGL2 in the transcrip-
tional activation of ASCL2, we constructed a fluorescent re-
porter vector with themouseAscl2 proximal promoter (Fig-
ure 6A). Assays in DLD1 cells revealed that constitutive
expression of PLAGL2 augmented reporter activity (Figures
6B and 6C), while siRNA knockdown of endogenous
PLAGL2 resulted in decreased activity (Figure 6D). To
examinedirect interaction,we employed chromatin immu-
noprecipitation (ChIP) to determine if PLAGL2 binds
conservedPLAGconsensus sites (GRGGCN6-8RGGK, aspre-
viously defined by Hensen et al., 2002; Voz et al., 2000)
located in the proximal mouse Ascl2 promoter and near a
30 lncRNA (Wintrlinc1) (Figure 6E). ChIP and qPCR revealed
clear interaction of PLAGL2 with the Ascl2 promoter in
both PLAGL2-O/E enteroid clones (Figure 6F). ChIP also
indicated interaction with the mouseWintrlinc1 promoter,
although only in enteroids expressing higher levels of
PLAGL2 (Figure 6F). Thus, PLAGL2 interacts with cis regula-
tory sequences near ASCL2 and can drive transcription of
the ASCL2 promoter.
(O) Quantification of lineage-tracing events in stable Cas9D10A-expressing enteroids 7 days after transfection with a transposon consti-
tutively expressing gRNAs targeting Plagl2 or LacZ (NS gRNA).
(P) Exemplary images of a lineage-tracing event from days 4 to 7 post-transfection (red arrow) described above, as observed via
constitutive GFP co-expression from the gRNA-expressing transposon. Single isolated transfected cells (black arrowhead) that do not
expand are not quantified as lineage-tracing events.
Student’s one-tailed t test was performed to evaluate significance between means of replicates, where *p < 0.05 and **p < 0.01.
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DISCUSSION
Here, we have reported the role for the transcription factor
PLAGL2 in promoting stem cell identity, in part through
direct transcriptional activation of ASCL2, which may
be responsible for Wnt-independent growth driven by
PLAGL2. Previously, known regulators of ASCL2 in the in-
testine were limited to the Wnt pathway transcriptional
activators TCF4/b-catenin (Schuijers et al., 2015) and
WiNTRLINC1, a long non-coding RNA (lncRNA) located
30 of ASCL2 that is also needed for human ASCL2 expres-
sion (Giakountis et al., 2016). The transcriptional activa-
tion of WiNTRLINC1 by TCF4/b-catenin is coupled with
the transcriptional activation of ASCL2, with the lncRNA
itself aiding in chromatin looping between TCF4/b-cate-
nin-bound WiNTRLINC1 and the ASCL2 promoter (Gia-
kountis et al., 2016). While we do not observe any change
of the mouse Wintrlinc1 RNA in PLAGL2-expressing
mouse enteroids (data not shown), the Wintrlinc1 pro-
moter itself may act in a facultative fashion as an enhancer
for ASCL2, independent of the Wintrlinc1 RNA. lncRNA
promoters have been documented to execute this type of
cis regulation of neighboring genes (Engreitz et al., 2016).
In vivo, a role for PLAGL2 in stem cell development
and/or homeostasis remains to be determined. Early in
murine post-natal intestinal development (post-natal
day 3, or p3) PLAGL2 protein appears to be distributed
throughout epithelial cells along the crypt-villus axis,
with mRNA levels dropping gradually after p14 (Van
Dyck et al., 2007). While mice homozygous for a germline
null mutation in Plagl2 die shortly after birth, the reason
for this mortality is unclear, and may be due to stem cell
failure, or due to epithelial lipid malabsorption, as pro-
posed previously (Van Dyck et al., 2007). In vivo, Plagl2-
null phenotypes caused by depletion ofWnt ligand expres-
sion may be masked by the unperturbed expression of
stromal-derived Wnts. A conditional (e.g., floxed) allele is
needed to determine the role of PLAGL2 in the adultmouse
intestinal epithelium through conditional inactivation.
In addition to direct regulationofASCL2, PLAGL2 also ap-
pears to drive Wnt signaling, although this effect appears
minimal in our overexpressionmodel; i.e.,Wnt target genes
are not globally increased, and TOP-tdT reporter activity is
only modestly increased. PLAGL2 O/E appears to augment
the abundance of Wnt-high cells, as gauged from our
confocal microscopy, which may reflect a compartmental-
ized effect of PLAGL2, perhaps onlywithin the IESC lineage.
TheWnt targetsCd44 and Axin2, which are not restricted to
the IESC lineage (Li et al., 2016; Zeilstra et al., 2014), may
only be increased in IESCs, which could be obfuscated by
expressionanalysisof totalRNAfromwholeenteroids.Alter-
natively, in the context of overexpression, PLAGL2-medi-
ated effects on canonical Wnt signaling may depend on
limiting co-factors. This could account for depletion of
Wnt targets in Plagl2 knockouts, but not increased abun-
dance of the same targets following PLAGL2 O/E. Previous
Figure 3. PLAGL2 Drives an Lgr5High Intestinal Stem Cell Signature and Wnt Activation
(A) Scatterplot of reads per kilobase of transcript per million mapped reads (RPKM) values from RNA-seq of mouse enteroids, clone no. 1
(PLAGL2-Low O/E) and clone no. 2 (PLAGL2-High O/E), compared with GFP-expressing (GFP-TG) enteroids. The number of genes down- or
upregulated >2-fold for each clone is indicated.
(B) GSEA using a gene set consisting of 600 transcripts upregulated >3-fold in PLAGL2 no. 2 enteroids, and upregulated >1.05-fold in
PLAGL2 no. 1 enteroids, relative to GFP-TG enteroids. Dataset is a ranked list of 3,566 transcripts from Lgr5-EGFP-sorted IESCs selected for
up- or downregulation, relative to Lgr5-EGFPLOW cells (p < 0.05) from a published dataset (Munoz et al., 2012).
(C) GSEA against all molecular function gene ontology (GO) terms revealed a strong ‘‘Frizzled Binding’’ enrichment in the RNA-seq dataset.
(D) Expression levels of Wnt ligand genes altered by PLAGL2 O/E, represented as RPKM values from RNA-seq data.
(E) RT-PCR validation of Wnt mRNA levels, expressed relative to GFP controls.
(F) RT-PCR for the Wnt target genes Cd44 and Axin2 in WT and Plagl2 mutant ileum enteroids.
(G) Schematic map of Tcf/Lef reporter (TOP-tdT) transposon that expresses tdTomato with a nuclear-localization signal (tdT-NLS).
(H and I) Representative images of stable lines of WT mouse enteroids with the TOP-tdT reporter treated for 48 hr with vehicle (0.1%
DMSO), 4 mM Chir99021, or 2 mM IWP-2 (H), with fluorescence quantified in (I).
(J–O) Confocal image of TOP-tdT fluorescence in jejunum enteroid clone A stably overexpressing PLAGL2 (J), with empty vector control A
depicted in (K). Confocal image of TOP-tdT fluorescence in ileum PLAGL2 O/E enteroid (L) (white), and overlaid in red with a nuclear stain
(M). Control enteroids (GFP O/E) are shown in (N) and (O).
(P) Enteroids from eight independent Piggybac transgenic lines were dissociated for quantifying fluorescence in each cell.
(Q) RT-PCR for the human PLAGL2 cDNA expressed in mouse ileum and jejunum enteroid lines, also transgenic for TOP-tdT.
(R) Images of GFP-labeled and PLAGL2 O/E ileum enteroids co-cultured together for 10 days.
(S) Enteroids overexpressing PLAGL2 or GFP were imaged for TOP-tdT reporter activity following 10 days of culture, with increased reporter
activity evident in GFP-expressing enteroids co-cultured with PLAGL2-expressing enteroids.
(T) PLAGL2 O/E enhances colony-forming potential of RFP-expressing (ROSA26mTmG) WT mouse enteroids following 72 hr of co-culture.
Scale bars, 50 mm. Student’s one-tailed t test was performed to evaluate significance between means of replicates, where *p < 0.05 and
**p < 0.01.
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Figure 4. PLAGL2 Drives Enteroid Growth and Survival in the Absence of Wnt
(A and B) GFP-expressing (A) or PLAGL2-O/E (B) enteroids were plated in ENR medium containing DMSO or 1 mM IWP2 and monitored over
7 days for viability. The vast majority of GFP-expressing enteroids are dead by 5 days with 1 mM IWP2 treatment (A) (yellow asterisks) while
rare surviving enteroids begin to regress by day 7 (A) (red arrow, and inset). Many PLAGL2-O/E enteroids survive 1 mM IWP2, mostly as
cysts, with some persisting as budding enteroids (B) (red arrow, and inset). Enteroid buds are indicated with arrowheads, and yellow
asterisks indicate dead enteroids.
(C) Quantification of surviving enteroids following 7 days of IWP-2 treatment, with morphological qualification of status (see Supple-
mental Experimental Procedures).
(D–F) Representative images of a TOP-tdT enteroid, overexpressing PLAGL2, imaged over 72 hr of treatment with 2 mM IWP-2 (D). Levels of
tdT were quantified in enteroids expressing either GFP (E) or PLAGL2 (F) over 4 days of treatment, after which tdT fluorescence was not
visible in any organoid treated with IWP-2.
(G) RT-PCR for stem cell markers Ascl2 and Lgr5 in TOP-tdT enteroids treated with 2 mM IWP-2 for 48 hr, relative to levels in enteroids
treated with 0.1% DMSO (Veh.).
(H) RT-PCR for Wnt target genes, as in (G).
(legend continued on next page)
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effects of PLAGL2 on Wnt ligand expression have also
been documented in glioma cells, although PLAGL2 drives
expression of Wnt6 in this model (Zheng et al., 2010). The
involvement of other PLAGL2 targets also cannot currently
be excluded as possible modulators of Wnt signaling.
It is rather enigmatic that PLAGL2 robustly induces
the expression of Wnt genes (Wnt9b, Wnt4, Wnt10a, and
Wnt5a) when overexpressed in enteroids, yet modestly aug-
ments canonical Wnt signaling. These Wnts may be minor
components compared with the larger pool of Wnt3 (or
Wnt2b, in vivo). In addition, robustWnt4 andWnt5a induc-
tion by PLAGL2may trigger the activation of non-canonical
Wnt signaling. TheseWnts can activate non-canonicalWnt
signaling pathways (Heinonen et al., 2011; Tanigawa et al.,
2011; Wallingford et al., 2001; Yamanaka et al., 2002) and
antagonize canonical signaling, which is observed for both
Wnt5a (Bernard et al., 2008; Topol et al., 2003; Yuzugullu
et al., 2009) and Wnt4 (Bernard et al., 2008; Tanaka et al.,
2011). In CRC,WNT5A is frequently downregulated, antag-
onizes canonical Wnt signaling, represses epithelial-to-
mesenchymal transition, and slows CRC cell line prolifera-
tion (Cheng et al., 2014). Consistent with this, Wnt5a is a
stromal signal that antagonizes epithelial proliferation of
wounded mucosa in the mouse colon but is necessary for
regeneration (Miyoshi et al., 2012).More studies of the roles
of eachWnt ligand are needed for the colon, which appears
more resistant to loss of all Wnt ligands, as observed
following global inactivation ofWntless (Wls) in themouse
(Farin et al., 2012). PLAGL2 may have differing effects in
these compartments (colon versus small intestine), in vivo,
perhaps due to unique contexts of specific Wnt ligands.
In future efforts to antagonize canonical Wnt signaling
in CRC tumors for therapeutic purposes, as underway in
mouse models (Cha and Choi, 2016; Fang et al., 2016; Ma-
suda et al., 2016; Qu et al., 2016; Yamada and Masuda,
2017), it may be necessary to consider pathways that drive
Wnt-independent maintenance of proliferation or a stem
cell-like state. PLAGL2 appears to drive such a pathway
andmay also be a relevant target for therapeutic inhibition.
EXPERIMENTAL PROCEDURES
Vector Construction
BII-ChPt and BII-ChBt vectors for Piggybac-mediated transgenesis
were constructed using standard molecular cloning techniques.
PLAGL2 was PCR amplified and cloned, in frame, between each
BsmBI restriction site (see Supplemental Information). LIN28B
was cloned into the PB533A-2 vector (SystemBiosciences) between
theXbaI and SwaI restriction sites after PCR amplification from the
MSCV-PIG-LIN28B vector (King et al., 2011). The pCMV-hyPBase
plasmid (Yusa et al., 2011) was a gift from Allan Bradley (Wellcome
Trust Sanger Institute).
Transgenic Organoid Production
Human organoids were established from biopsies obtained from
healthy patients undergoing routine colonoscopy, cultured as
described previously (Matano et al., 2015), and transfected with
the PB533A-LIN28B (transfected at passage 8) or BII-ChBt-PLAGL2
(transfected at passage 10) using previously described protocols
(Fujii et al., 2015).
Mouse jejunum enteroids established from 6- to 8-week-old
C57BL/6 mice were transfected with the BII-ChPt-PLAGL2 or -GFP
Piggybac transposons at passage 3. Enteroids were transfected with
1 mg DNA (200 ng pCMV-hyPBase, 800 ng BII-ChPt-PLAGL2, or
BII-ChPt-GFP) by spinoculation as described previously (Schwank
et al., 2013) using lipofectamine 2000 (Thermo Fisher Scientific).
All experiments for human or mouse organoids (transgenic,
knockout, or WT) were performed between passages 4 and 12.
RNA Isolation and RT-PCR
Cells/enteroids were homogenized in 1.0 mL TRIzol (Thermo
Fisher Scientific) for 30–45 s using a BeadBug homogenizer (Bench-
mark Scientific), and total RNA isolated per the manufacturer’s
specifications. RT reactions were performed with oligo(dT) primers
using 1–4 mg RNA and Superscript III (Thermo Fisher Scientific).
qPCR was achieved with Bullseye EvaGreen qPCR MasterMix
(MIDSCI) using primers in Table S2.
Colony-Forming Assays
For human organoid colony-forming assays, organoids were
dissociated in TrypLE Express (Thermo Fisher Scientific) contain-
ing 250 U/mL DNase I and 10 mM Y27632 for 20 min at 37C.
Single cells were plated in quadruplicate at 5,000 cells/well on a
24-well plate. Images were taken and quantified at day 0 and
day 7 (LIN28B organoids) or day 10 (PLAGL2 organoids) using
the BioTek Cytation 3 Imaging Platform. Mouse enteroids were
also dissociated with TrypLE, for 5 min, and plated/imaged as
above.
Mutagenesis of Plagl2 in Mouse Enteroids
For generating knockouts of mouse Plagl2 C57BL/6 jejunum
and ileum enteroids (from 6- to 8-week-old mice, each at passage
no. 1)were expanded for transfection as described above. Enteroids
were dissociated into single cells with TrypLE (Thermo Fisher Sci-
entific) and transfected with Cas9 plasmids, pCMV-hyPBase, and
BII-ChPtG. Transfectants were selected with 2 mg/mL puromycin
and picked after 7 days.
(I and J) TOP-tdT enteroids were treated 6 days with 2 mM IWP-2 and then 14 days in complete ENR medium (I), followed by microscopic
imaging (J).
(K) Quantification of enteroids from (J), relative to the original numbers of enteroid colonies present prior to IWP-2 treatment.
Scale bars, 50 mm. Student’s one-tailed t tests were performed to evaluate significance between means of replicates, where *p < 0.05 and
**p < 0.01.
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Figure 5. PLAGL2 Enhances ASCL2 Expression, Independent of Canonical Wnt Signaling
(A–C) Heatmap reflecting RNA-seq data from clone no. 1 (PLAGL2-Low O/E, middle column) and clone no. 2 (PLAGL2-High O/E, right
column) showing expression changes of TCF4/b-catenin and ASCL2 transcriptional targets relative to GFP control (A). RT-PCR was per-
formed for canonical Wnt target genes, Axin2 and Cd44 (B), human PLAGL2 and Ascl2 (C) in mouse enteroids, clones no. 1 and 2.
(D) RT-PCR for ASCL2 in human PLAGL2-O/E colonoids.
(E) GSEA against a gene set of mRNAs induced upon Ascl2 overexpression (Schuijers et al., 2015) revealed enrichment in the PLAGL2 RNA-
seq dataset (clone no. 2).
(legend continued on next page)
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Transient Mutagenesis of Plagl2 and Lineage Tracing
in Mouse Enteroids
Mouse enteroids were first transfected and selected for
stable expression of theCas9 nuclease. This line of Cas9-expressing
enteroids was then transfected with a Piggybac transposon driving
constitutive expression of specific gRNAs and GFP. GFP expression
and lineage-tracing events were imaged on days 4–7 after transfec-
tion, and lineage-tracing events quantified.
IWP2 Treatment of PLAGL2 Mouse Enteroids
BII-ChPt-PLAGL2mouse enteroidswere plated onto a 12-well plate
(Greiner) in ENR-containing vehicle (0.1% DMSO), or the Wnt
(F) RT-PCR for Ascl2 and Lgr5 in mouse Plagl2 mutant enteroids.
(G) RNA-seq data of one TCGA CRC patient cohort (N = 182), with tumors stratified according to activating Wnt pathway mutations
(missense mutations in CTNNB1 or truncating mutations in APC or AXIN2).
(H) RT-PCR for ASCL2 in DLD1 CRC cells with PLAGL2 heterozygous or homozygous null mutations.
(I) Quantification of lineage-tracing events in stable Cas9D10A-expressing mouse enteroids 7 days after transfection with a transposon
expressing gRNAs against Plagl2, and co-transfected for stable constitutive expression of ASCL2 (conferring blasticidin resistance).
(J) T7E1 assay of PCR products from the targeted (exon 3) region of Plagl2 from blasticidin-resistant enteroids from (I).
(K) Illumina sequencing of targeted region of Plagl2 from enteroids in (I) confirms mutagenesis of Plagl2, with vast majority of mutations
consisting of insertions or deletions (indels). Targeted region in Plagl2 amplicon by each unique gRNA (for paired nickase with Cas9D10A) is
indicated with arrowheads.
Student’s one- or two-tailed t test was performed to evaluate significance betweenmeans of replicates, where *p < 0.05 and **p < 0.01. See
also Figures S1 and S2.
Figure 6. PLAGL2 Activates Transcription of the Mouse Ascl2 Promoter and Directly Binds Sites near Ascl2
(A) Reporter transposon construct for measuring Ascl2 promoter activity.
(B) Ascl2 promoter activity as measured in DLD1 cells, after co-transfection with PLAGL2 expression construct or empty vector.
(C) Images of RFP and GFP fluorescent DLD1 cells from (B).
(D) siRNA knockdown of endogenous PLAGL2 in DLD1 cells following stable integration of the Ascl2 promoter reporter, pictured in (A).
Reporter activity was measured 72 hr after siRNA transfection.
(E) Map of mouse chromosome 7 showing locations of Ascl2, Wntrlinc1, and Th genes and sites where two conserved PLAGL2 consensus
sequences (GRGGCN6-8RGGK) are located.
(F) Chromatin immunoprecipitation and qPCR for sequences encompassing these sites using lysates from PLAGL2 O/E (clones no. 1 and 2)
and GFP-expressing mouse enteroids. Sequences within Th intron 3 were amplified as negative controls.
Scale bar, 500 mm. Student’s one-tailed t test was performed to evaluate significance between means of replicates, where *p < 0.05 and
**p < 0.01.
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inhibitor, IWP-2 (Selleckchem) at 1 or 2 mM.Mediumwas changed
every 48 hr. Enteroids were imaged daily for 7 days using a BioTek
Cytation 3 Imaging PlatformwithGen5 software tomonitor enter-
oid viability.
Transfection with siRNA (for Knockdown) or miRNA
Mimics
Transient transfection of DLD1 cells with the Let-7b mimic (IDT)
was performed as follows. A total of 5 3 105 cells was plated in a
six-well plate and transfected the next day with 1.25 mL of 20 mM
miRNAs using the Lipofectamine RNAiMAX (Thermo Fisher Scien-
tific) transfection reagent according to the manufacturer’s instruc-
tions at a final concentration of 10 nM. After 72 hr, cells were ho-
mogenized in TRIzol and RNA isolated for RT-PCR.
mRNA-Seq
Data from thesemRNA-seq experiments are available at theGEO at
the NIH under accession number GEO: GSE115532.
Vertebrate Animals
Mouse models used in this study conform to standards of care and
ethical treatment as determined by the Washington University
Institutional Animal Care and Use Committee. The investigators
sought and received approval for animal protocols in this study.
Statistical Methods
Statistical considerations are given for a parallel study of two
groups, for pairwise comparison of two conditions, genotypes, or
treatments. For comparison of two groups in a parallel design, per-
formed in triplicate, we have a 90% likelihood of detecting a signif-
icant difference (p < 0.05) between groups if the true difference is
2.95 times the SD. This power calculation uses the non-central
t-function distribution. Pairwise comparisons use Student’s t test,
either one- or two-tailed, depending on the initial hypothesis. As-
says were performed three times for each experiment, in triplicate
or quadruplicate. Data are represented as the mean, with error bars
depicting the SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and three tables and can be found
with this article online at https://doi.org/10.1016/j.stemcr.2018.
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Figure S1. PLAGL2 Expression Correlates with Multiple Stem Cell Markers in Colorectal Cancers and 
Adenomas. Related to Figure 5. A) Scatter plots of PLAGL2 mRNA expression vs. stem cell markers as 
determined from RNA-seq data of CRC tumors from TCGA (Cancer Genome Atlas 2012). Regression analysis 
indicates a significant positive correlation between these markers and PLAGL2. B) Scatter plots of PLAGL2 mRNA 
expression vs. stem cell markers as determined from Affymetrix microarray analysis of a panel of 27 patient-derived 
colorectal cancer explants (PDCCEs) performed by Uronis et al. (Uronis et al. 2012). Regression analysis indicates a 
significant positive correlation between ASCL2, RNF43, NOTCH1, and PLAGL2. C) Scatter plots of PLAGL2 
mRNA expression vs. stem cell markers as determined from Affymetrix microarray analysis of 32 colorectal 
adenomas along with matched normal tissue from the same patients performed by Sabates-Bellver et al. (Sabates-
Bellver et al. 2007). 
  
 
 
Figure S2. Mutagenesis of PLAGL2 in DLD1 CRC Cells. Related to Figure 2, 3, and 5.  A) The human PLAGL2 
gene was targeted using the CRISPR/Cas paired nickase in conjunction with SRIRACCHA enrichment using the 
Piggybac DNA transposon (Wen et al. 2017). Top) Schematic of target site within the PLAGL2 gene with each 
CRISPR/Cas paired nickase half site indicated in blue and PAM depicted in pink. Middle) Illumina deep sequencing 
of DLD1 mutant clone #3, which revealed two mutations, one with an in-frame 12 nt deletion, and another mutation 
with an out-of-frame insertion of 4 nt. Bottom) Illumina deep sequencing of DLD1 mutant clone #XX, which 
revealed two mutations, one with an out-of-frame deletion of 1 nt, and another mutation with an out-of-frame 
deletion of 25 nt. B) The mouse Plagl2 gene was targeted using CRISPR/Cas in C57BL/6 ileum and jejunum 
enteroids. Top) Schematic of target site within the Plagl2 gene with the CRISPR/Cas site indicated in blue and 
PAM depicted in pink. Three mutants were identified and used for experiments. Mutations identified from Illumina 
sequencing are indicated for clones #4, 7, and 3. Clone #4 possessed two frame-shift mutations. Clone #7 possessed 
two mutations, one of which generated a frame-shift. Lastly, clone #3 possessed a D197H missense mutation. 
  
Table S1. Oligos and PCR primers used for Cloning. Related to Experimental Procedures. 
Primer/Oligo Name Sequence Purpose 
hPLAGL2_1221(F) ATCCTCACCTATCTCTTCCCC Cloning human PLAGL2 
3’UTR hPLAGL2_5777(R) TTTTACTGTCTGCCCTACGC 
SacII_PLAGL23pUTR(F) TCTCTTCCGCGGCTCAGCTCCCTCCAAAATA  Cloning human PLAGL2 
3’UTR 
MluI_PLAGL23pUTR(R) 
TGCCCTACGCGTACCATCATCCTGGATGC
TAAAG 
PLAGL2_Let7s1_Kpn(S) 
CTCCAAAATACCAGCTTGGATCGGTACC
ATACTTGCCCGACAAATTGCCC 
Site directed mutagenesis of 
Let-7 site #1 
PLAGL2_Let7s1_Kpn(AS) 
GGGCAATTTGTCGGGCAAGTATGGTACC
GATCCAAGCTGGTATTTTGGAG 
PLAGL2_Let7s2_Kpn(S) 
CTCTGATTCAGAAACACACTTCGGTACCT
TTACTGTTAACTCTTAACAGA 
Site directed mutagenesis of 
Let-7 site #2 
PLAGL2_Let7s2_Kpn(AS) 
TCTGTTAAGAGTTAACAGTAAAGGTACC
GAAGTGTGTTTCTGAATCAGAG 
SfiI_Ascl2-1191(F) 
CTAAAGGGCCTCCATGGCCTGGAAGTTT
GAAGG 
Cloning mouse Ascl2 proximal 
promoter. 
SfiI_Ascl2+312(R) 
GTTCATGGCCTAGTGGGCCTGCTTCCATG
CTCCGGGC 
PLAGL2_TS_T1(F2) TGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCTATCTCCCCTCTTTCTGCTTTC 
For PCR of PLAGL2 mutations 
and Illumina Sequencing 
PLAGL2_TS_T1(R2) ACACTCTTTCCCTACACGACGCTCTTCCG
ATCTTTGTTAGGATCATGGGTCTGC 
PLAGL2_BsmBI(F) 
TGCCATCGTCTCAGGCATGACCACATTTT
TCACCAGC 
For PCR amp of hPLAGL2 for 
cloning into expression vectors. 
PLAGL2_BsmBI(R) 
AGGCTCCGTCTCGTAGCCAAAAACTGAG
CTGAGG 
XbaI-hLIN28B(F) GCCTACTCTAGAGCCACCATGGCCGAAG
GC 
For PCR amp of hLIN28B for 
cloning into expression vectors. 
EcoRV-hLIN28B(R) GGCCGCGATATCCGATTTGGCTAGCTTAT
GTCTTTTTCC 
hASCL2_BbsI(F) 
CTCTAGGAAGACCCGGCATGGACGGCGG
CACAC 
For PCR amp of hASCL2 for 
cloning into expression vectors. 
hASCL2_BbsI(R) 
ATTCGAGAAGACCATAGCTCGAGGGCGC
TCAGTAG 
BsaI_GGCA_NLS_Cas9(F) 
CGATGTGGTCTCCGGCATGTCGCCGAAG
AAAAAGCGCAAG 
For PCR amp of Cas9D10A for 
cloning into expression vectors. 
BsaI_ACTC_Cas9(R) 
TCATGTGGTCTCCACTCGTATCGATAATT
CTTAGCTGGCCTC 
mPlagl2_T5PSL(S) CACCGTATAGAACCGCCTGTCACAA  For cloning Plagl2-specific 
gRNAs into pBS-U6gRNA mPlagl2_T5PSL(AS) AAACTTGTGACAGGCGGTTCTATAC 
mPlagl2_T5PSR(S) CACCGGATGTCCGACGGCACCTAG For cloning Plagl2-specific 
gRNAs into pBS-U6gRNA mPlagl2_T5PSR(AS) AAACCTAGGTGCCGTCGGACATCC 
LacZOm_T3PSL(S) CACCGAAGGCGGCGGGCCATTACC For cloning LacZ-specific 
gRNAs into pBS-U6gRNA LacZOm_T3PSL(AS) AAACGGTAATGGCCCGCCGCCTTC 
LacZOm_T3PSR(S) ACACCGCGTTCGACCCAGGCGTTAG For cloning LacZ-specific 
gRNAs into pBS-U6gRNA LacZOm_T3PSR(AS) AAAACTAACGCCTGGGTCGAACGCG 
BglI_U6gRNA(F) GGAAAAGGCCTCCAGGGCCGCCCCCTTC
ACCGAGGGCCTATTTCCC 
For PCR of U6gRNAs from 
pBS-U6gRNA for cloning into 
BII-gR-PGW. BglI_U6gRNA(R) CTGCAGGCCTTGGAGGCAAAAACAAAAA
AGCACCGAC 
 
 
 
Table S2. RT-PCR primers. Related to Experimental Procedures. 
Primer/Oligo Name Sequence Purpose 
PLAGL2(F) CAGAGACCATATAGCTGCCC RT-PCR for PLAGL2 
PLAGL2(R) CCTTGCGGTGAAACATCTTATC 
ASCL2(F) CGTTCCGCCTACTCGTC RT-PCR for ASCL2 
ASCL2(R) TGAGGCTCATAGGTCGAGG 
HMGA2(F) CTATCACCTCATCTCCCGAAAG RT-PCR for HMGA2 
HMGA2(R) GTTGTCCCTGGGCTGAAG 
B2M(F) TCGCGCTACTCTCTCTTTCT RT-PCR for B2M 
B2M(R) TTTCCATTCTCTGCTGGATGAC 
PPIA(F) TGCAGACAAGGTCCCAAAG RT-PCR for PPIA 
PPIA(R) CCTGACACATAAACCCTGGAATA 
mWnt9b(F) GTGTGGTGACAATCTGAAG RT-PCR for mouse Wnt9b 
mWnt9b(R) TCCAACAGGTACGAACAG 
mWnt4(F) AGTGCCAATACCAGTTCCG RT-PCR for mouse Wnt4 
mWnt4(R) AGAGATGGCGTATACAAAGGC 
mWnt10a(F) CGCTTCTCTAAGGACTTTCTGG RT-PCR for mouse Wnt10a 
mWnt10a(R) GTGGCATTTGCACTTACGC 
mWnt5a(F) CGCTAGAGAAAGGGAACGAATC RT-PCR for mouse Wnt5a 
mWnt5a(R) CTCCATGACACTTACAGGCTAC 
Ascl2(F) GGCTGCTCTGAGCCTACCT RT-PCR for mouse Ascl2 
Ascl2(R) TAGGTCCACCAGGAGTCACC 
Axin2(F) TAGGTTCCGGCTATGTCTTTG RT-PCR for mouse Axin2 
Axin2(R) TGTTTCTTACTCCCCATGCG 
Cd44(F) TTCATCCCAACGCTATCTGTG RT-PCR for mouse Cd44 
Cd44(R) CGAAGGAATTGGGTAGGTCTG 
Wintrlinc1(F) TTGCTGAAAGGACTGGTCTG RT-PCR for mouse Wintrlinc1 
Wintrlinc1(R) GGATGTGGGTGAAGTGGAC 
Hprt(F) CCCCAAAATGGTTAAGGTTGC RT-PCR for mouse Hprt 
Hprt(R) AACAAAGTCTGGCCTGTATCC 
Tbp(F) CACCAATGACTCCTATGACCC RT-PCR for mouse Tbp 
Tbp(R) CAAGTTTACAGCCAAGATTCACG 
 
Table S3. Oligos used for gRNA Cloning/Generation. Related to Experimental Procedures. 
Primer/Oligo Name Sequence Purpose 
PLAGL2_T1PSR(S) CACCGTTCACCGCAAGGACCATCTG PLAGL2 gRNA T1 oligos for 
cloning into pBS-U6gRNAx2 PLAGL2_T1PSR(AS) AAACCAGATGGTCCTTGCGGTGAAC 
PLAGL2_T1PSL(S) ACACCGTCACAGTACATACACTGGTGG PLAGL2 gRNA T1 oligos for 
cloning into pBS-U6gRNAx2 PLAGL2_T1PSL(AS) AAAACCACCAGTGTATGTACTGTGACG 
PLAGL2_T2PSR(S) CACCGATCTCATACCGTAGGACTTC PLAGL2 gRNA T2 oligos for 
cloning into pBS-U6gRNAx2 PLAGL2_T2PSR(AS) AAACGAAGTCCTACGGTATGAGATC 
PLAGL2_T2PSL(S) ACACCGTTTCACGGGGTTGGGGCTCAG PLAGL2 gRNA T2 oligos for 
cloning into pBS-U6gRNAx2 PLAGL2_T2PSL(AS) AAAACTGAGCCCCAACCCCGTGAAAC
G 
PLAGL2_T1(S) GTGACCCCACCAGTGTATGTACTGTGA
TAAGATGTTTCACCGCAAGGACCATCT
GCG 
CRISPR/Cas9 target site 1 oligos for 
cloning into BII-C3HTK 
PLAGL2_T1(AS) GTCACCGCAGATGGTCCTTGCGGTGAA
ACATCTTATCACAGTACATACACTGGT
GGG 
PLAGL2_T2(S) GTGACCTTGAGCCCCAACCCCGTGAAA
AGATCTCATACCGTAGGACTTCAG 
CRISPR/Cas9 target site 2 oligos for 
cloning into BII-C3H2B 
PLAGL2_T2(AS) GTCACCTGAAGTCCTACGGTATGAGAT
CTTTTCACGGGGTTGGGGCTCAAG 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Vector Construction 
The BII-ChBt and BII-ChPt Piggybac transposon vectors consist of the CpG-less human EF1alpha 
promoter downstream of the CMV enhancer (ChEf1a promoter, Invivogen Inc.) a Blasticidin (ChBt) or Puromycin 
(ChPt) resistance cassette, the T2A peptide, a Flag (ChBt) or HA (ChPt) epitope tag, and a cloning site 
(AGCGGCATGAGACGGATAGCTCGTCTCAGCTA) for cDNA expression. 
 
Fluorescent Reporter for Assaying miRNA Effects on the PLAGL2 3’ UTR 
 A Piggybac DNA transposon vector (BII-BCnDFP) was generated, consisting of CMV-driven 
expression of puromycin N-acetyltransferase fused via a T2A self-cleaving peptide to a destabilized nuclear-targeted 
tandem Tomato (DD-tdT-NLS) red fluorescent protein. The destabilization domain (DD) is a 107-amino acid 
sequence from the FKBP1A protein possessing the L106P and F36V mutations (Egeler, Urner et al. 2011). 
Downstream of DD-tdT-NLS is the miRNA, such as Let-7a, for constitutive expression. The Let-7a chimeric 
shRNA (Let7a155) contains a modified terminal loop from mir155, as previously described (Madison, Liu et al. 
2013), and was cloned from a BamHI and XhoI fragment from the pcDNA6.2-Let-7a vector and inserted upstream 
of the SV40 late polyadenylation signal. As a negative control, a non-specific shRNA was similarly cloned from the 
pcDNA6.2-GW/EmGFP-miR vector (Thermo Fisher Scientific). Downstream of this is a CMV-driven destabilized 
EGFP (dGFP) protein with a 40-amino acid PEST destabilization domain (from the mouse ODC protein) fused to 
the EGFP C-terminus, as previously characterized (Li, Zhao et al. 1998). Downstream of this is a multiple cloning 
site (MCS) containing restriction sites for SacII, ApaI, MluI, KpnI, and XbaI, followed by two copies of the 240 bp 
chicken beta globin hypersensitive site IV core insulator element (Chung, Bell et al. 1997). To construct a Let-7 
sensitive synthetic reporter with Let-7 recognition sequences, a Let-7 sponge sequence and bovine growth hormone 
polyadenylation signal (BGHpA) were PCR amplified from the pRNA-U6-let7 sponge (gift from Phillip Zamore, 
Addgene plasmid # 35664) and cloned into the XbaI site in BII-BCnDFP. 
 
Assaying Ascl2 Promoter Activity with a Fluorescent Reporter 
To construct the BII-BCA vector for assaying Ascl2 promoter activity, the 5’ CMV promoter was removed 
and replaced with one copy of the 240 bp chicken beta globin hypersensitive site IV core insulator element (Chung, 
Bell et al. 1997), followed by the human adenovirus type 2 splice acceptor and the polyadenylation signal from the 
HSV thymidine kinase gene, and two copies of a directional polylinker consisting of two SfiI sites. The 3’ CMV was 
replaced with the CpG-less human EF1alpha promoter downstream of the CMV enhancer (ChEf1a promoter, 
Invivogen Inc.). 
 
Human and Murine Organoid Culture Medium 
 Human organoids were maintained in basal medium (Advanced DMEM/F12, 1x Penicillin/Streptomycin, 
1x Glutamax, 1x HEPES) containing R-spondin-1 (10%), Noggin (10%), Wnt3a (25%), 50ng/mL EGF (Cat # 236-
EG, R&D Systems), 0.5!M A83-01 (Tocris), 10nM Gastrin (Millipore-Sigma), 1mM N-Acetylcysteine (Millipore-
Sigma), 3!M SB202190, and 1x B27 (collectively termed WENRAS). For colony formation assays, human 
organoids were cultured for 4-5 days prior in basal medium containing R-spondin-1 (10%), Noggin (10%), 50ng/mL 
EGF (Cat # 236-EG, R&D Systems), 0.5!M A83-01 (Tocris), 10nM Gastrin (Millipore-Sigma), 1mM N-
Acetylcysteine (Millipore-Sigma), and 1x B27 (termed differentiation medium, ENRA). Noggin, R-spondin1, and 
Wnt3a conditioned media were produced as previously described (Wen, Liao et al. 2017). 
Murine enteroids were established from cultured crypts freshly isolated from 6-8 week old C57BL/6 mice, 
which were maintained on a 12 hour light/dark cycle and provided with food (standard mouse chow) and water, ad 
libitum. Enteroids maintained in ENR medium containing R-spondin-1 (10%), Noggin (10%), 50ng/mL EGF (Cat # 
236-EG, R&D Systems), 1mM N-Acetylcysteine (Millipore-Sigma), 1x N2, and 1x B27 (Sato, Vries et al. 2009). 
Prior to transfection, murine enteroids were expanded for 3 days in ENR medium supplemented with 10 mM 
nicotinamide and 25% Wnt3a conditioned medium (ENRW-Nic). 
 
Human Organoid Transfection 
Organoids were cultured 72 hours in medium without Wnt3a containing 4 !M Chir99021 (ENRAS-C), 
then with 10 !M Y27632 (ENRAS-CY) for 48 hours, and 1.25% dimethylsulfoxide (ENRAS-CYD) 24 hours prior 
to transfection. Organoids were dissociated for 20 minutes in TrypLE Express (Thermo Fisher Scientific), then 
spinoculated for 1 hour in 24-well plates at 600 x g, at 26° to 32°C, with 1 !g DNA (200 ng pCMV-hyPBase, 800 
ng BII-ChPt-PLAGL2 or PB533A-LIN28B) and 3 !l Lipofectamine 2000 in 500 !l ENRAS-CYD. After 10 days in 
culture, Puromycin/G418 resistant colonies were individually expanded and expression verified by RT-PCR. 
 
Colony Forming Assays 
For human organoid colony forming assays, organoids were dissociated in TrypLE Express (Life 
Technologies) containing 250 U/mL DNase I (1:200, NEB) and 10 !M Y27632 (Selleck Chemicals) for 20 minutes 
at 37ºC. Cells were then incubated at room temperature in basal medium (Advanced DMEM/F12, 1x 
Penicillin/Streptomycin, 1x Glutamax, 1x HEPES) containing DNase I and Y27632 for 5 mins with periodic 
vortexing. Single cells were plated in quadruplicate at 5,000 cells/well on a 24-well plate (Greiner) in 80% Matrigel, 
20% ENR with 10 !M Y27632, and overlaid with WENRAS plus 10 !M Y27632. Y27632 was removed on day 4 
post- plating. Images were taken and quantified at day 0 and day 7 (LIN28B organoids) or day 10 (PLAGL2 
organoids) post-plating using a Biotek Cytation3 Imaging Platform with Gen5 software.  
For mouse enteroid colony forming assays, enteroids were dissociated in TrypLE Express containing 250 
U/mL DNase I and 10 !M Y27632 for 5 minutes at 37ºC. Cells were then incubated at room temperature in ENR 
containing DNase I and Y27632 for 5 mins with periodic vortexing. Single cells were plated in quadruplicate at 
5,000 cells/well on a 24-well plate in 80% Matrigel, 20% ENR with 10 !M Y27632, and overlaid with ENR plus 10 
!M Y27632. Y27632 was removed on day 4 days post-plating. Cultures were imaged and quantified on days 0 and 
7 post-plating using a Biotek Cytation3 Imaging Platform with Gen5 software. 
 
Preparation of Sections for EdU Staining 
To de-paraffinize, sections were washed for 5 minutes each in Histoclear 3x, 100% ethanol 2x, 90% 
ethanol 1x, 70% ethanol 1x, 50% ethanol 1x, dH2O 1x, and 1x PBS 3x. Antigen retrieval was performed by 
incubating sections in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) in a pressure cooker 
for 5 minutes at high pressure, cooled to room temperature, then rinsed 3x in 1x PBS. 
 
Mutagenesis of Plagl2 in Mouse Enteroids 
 For generating knock-outs of mouse Plagl2 C57BL/6 jejunum and ileum enteroids (from 6-8 week old 
mice, each at passage #1) were expanded for transfection as described above. Enteroids were transfected with 500 
ng hCas9 (Addgene Plasmid # 41815), 300 ng of BII-ChPtG (encoding GFP), 100 ng of pBS-U6-gRNA (Wen, Liao 
et al. 2017), and 100 ng of pCMV-hyPBase. Selection with Puromycin (Invivogen, 2 !g/ml) was initiated 72 hours 
after transfection. After 7 days Puromycin selection, individual colonies were picked, and expanded for genotyping 
by Illumina sequencing. Genomic DNA (gDNA) was extracted and the targeted region of Plagl2 was amplified by 
PCR with Q5 DNA polymerase for amplicon Illumina sequencing through the Washington University Center for 
Genomic Sciences. Sequence was analyzed using CRISPresso (Pinello, Canver et al. 2016) to characterize any 
mutant alleles. Two mutant ileum enteroid clones were identified, one (#4) with no WT allele detected, but only two 
frame-shift alleles, while the other clone (#7) also had no detectable WT allele but possessed only one out-of-frame 
allele, and is suspected to be a functional heterozygote. One mutant jejunum clone (#3) had one missense mutation 
and is also a suspected functional heterozygote, but because this jejunum Plagl2 mutant allele may not represent a 
loss of function mutation, most experiments were performed on the ileum enteroid Plagl2 mutants. Enteroid growth 
of mutants was quantified using the Biotek Cytation3 and colony forming assays were performed as above. Enteroid 
clones targeted with Plagl2 gRNAs, which exhibited no mutations by Illumina sequencing, were used as WT 
controls. For RT-PCR RNA was extracted from WT control and Plagl2 mutant enteroids using Trizol (Thermo 
Fisher Scientific). RT reactions were performed on 1-3 !g total RNA with Superscript III (Thermo Fisher Scientific) 
and oligo dT primers, followed by QPCR with Bullseye Evagreen 2x QPCR Mix (MidSci). 
 
Transient Mutagenesis of Plagl2 and Lineage Tracing in Mouse Enteroids 
 Enteroids constitutively expressing Cas9D10A were first generated by integrating a stable Piggybac 
transgene, BII-ChPt-Cas9D10A, into C57BL/6 jejunum enteroids (from 6-8 week old mice, at passage #4). The 
Cas9D10A nickase variant was implemented here to minimize the chances of off-target gRNA-independent mutations 
that might be caused by constitutive long-term nuclease expression in enteroids (Ran, Hsu et al. 2013). All 
Puromycin-surviving clones (n = 12) were pooled and expanded for subsequent transfection with a gRNA-
expressing transposon. Expression of the HA-tagged Cas9D10A nickase in these enteroids was confirmed by 
immunoblot (data not shown) as described above. The BII-ChPtG vector was modified for gRNA expression by 
cloning a PCR fragment for two U6-gRNA expression cassettes from the pBS-U6-gRNA vector, containing gRNAs 
against the Plagl2 gene or bacterial beta-galactosidase, LacZ (NS control). The two cassettes were ligated together 
through unique BsaI sites, cut with BglI, and then cloned into a unique SfiI site located within the BII-ChPtG vector, 
just upstream of the ChEf1a promoter. This generated the BII-gRx2-PtG vector. For lineage tracing experiments, 
Cas9D10A enteroids were transfected with 200 ng pCMV-hyPBase and 800 ng of a BII-gRx2-PtG vector targeting the 
Plagl2 gene or LacZ (NS control). After transfection, enteroids were plated in a 6-well plate, in triplicate, and were 
imaged daily using the Biotek Cytation3 for EGFP fluorescence and brightfield images beginning 4 days after 
transfection. At 7 days after transfection, the number of GFP-positive lineage tracing events was quantified by 
counting the number of GFP-positive clones having a size greater than >150 !m in diameter, and qualitatively 
comprising a whole organoid, or a part of an organoid, including at least one or two whole buds. For simultaneous 
over-expression of ASCL2 for rescue, enteroids (passage #) were transfected as above with 200 ng pCMV-hyPBase, 
400 ng of a BII-gRx2-PtG vector, and 400 ng of a BII-ChBt-ASCL2/BII-ChBt (empty). Enteroids were plated in a 
6-well plate, as above, in triplicate and selection with 5 !g/ml Blasticidin was initiated at 72 hours and the numbers 
of initial live enteroids were quantified using the Cytation3. Enteroids were imaged every 48 hours for 7 days, and 
GFP-positive clones were quantified as above on day 7. Percentages of GFP-positive clones were expressed relative 
to the numbers of initially live enteroids, prior to Blasticidin. Blasticidin resistant colonies were pooled and 
genotyped as above by Illumina sequencing and analyzed using CRISPResso (Pinello, Canver et al. 2016)). Mutant 
alleles were quantified as present if such mutations yielded 10 or more reads per mutation. Genomic DNA was also 
analyzed for indels at Plagl2 by T7E1 assay, as previously described (Wen, Liao et al. 2017). 
 
Wnt Reporter (TOP-tdT) Construction and Transfection 
The promoter and TCF/Lef sites from the M50 Super 8x TOPFlash vector (a gift from Randall Moon, 
Addgene plasmid # 12456, (Veeman, Slusarski et al. 2003)) was PCR amplified with Q5 polymerase (NEB) with 
primers containing BglI sites, and cloned into the unique SfiI sites of the BII-BCA vector, to create the BII-BCA-
TOPFlash vector. The destabilization domain of tdTomato and the EGFP expression cassette were then each deleted 
by site-directed mutagenesis to create the BII-TOP-tdT vector. 
Transection of mouse ileum or jejunum enteroids with pCMV-hyPBase (200 ng), BII-TOP-tdT (400 ng), 
and BII-ChPt-PLAGL2 (400 ng) was performed at passage 4. Negative controls were either empty vector (BII-ChPt) 
or BII-ChPt-EGFP. After 7 days selection with Puromycin (Invivogen, 2 !g/ml), individual RFP-positive colonies 
were picked, expanded, and verified for expression of human PLAGL2 by RT-PCR. Fluorescence in enteroids was 
measured in organoids by three methods: 1) enteroid  colonies were imaged using the Cytation3, and total and mean 
tdTomato fluorescence was calculated for each enteroid using Gen5 software, 2) enteroids were dissociated 5 
minutes with TrypLE (Thermo Fisher Scientific) containing 10 !M Y27632, neutralized with an equal volume of 
ENR medium containing 10 !M Y27632, centrifuged 45 seconds at 1500 x g, and re-suspended in 15 !l complete 
ENR medium containing 10 !M Y27632, cover-slipped onto Superfrost Plus (Thermo Fisher Scientific) microscope 
slides, and tdTomato fluorescence measured by imaging single cells with the Cytation3, 3) live enteroids in 35 mm 
tissue culture dishes were passaged and imaged at 72 hours after a 1 hour incubation with 5 !g/ml Hoechst 33342 
(Thermo Fisher Scientific). Organoid cultures were visualized using an upright Zeiss Examiner.Z1-based 880 LSM 
with a 20x/1.0 water-immersion objective. Hoechst dye was excited using a 405 nm diode laser and tdTomato was 
excited with a 561 nm DPSS laser. Optical sections (0.5 !m) were acquired with an Airyscan super-resolution 
detector and were processed using ZEN Blue v. 2.3.  
 
Enteroid Co-Culture 
 For examining effects on Wnt signaling through secreted factors, control EGFP-expressing enteroids 
possessing the TOP-tdT reporter were cultured in ENR medium in a 50/50 mixture with PLAGL2-expressing 
enteroids or alone, in 24-well plates (Greiner), in quadruplicate. Cultures were then imaged at days 0, 2, 6, 8, and 10 
for EGFP and tdTomato fluorescence. For co-culture and colony forming assays, PLAGL2-expressing enteroids 
(clone #1 and #2) were incubated in a 50/50 mix with WT jejunum enteroids established from R26mTmG mice 
(passage #3), which constitutively express membrane-localized tdTomato. After 72 hours of co-culture, enteroids 
were dissociated and 10,000 cells were plated per well in a 24-well plate, in quadruplicate. At d0, just after plating 
in matrigel, tdTomato positive R26mTmG cells were counted with the Cytation3 to quantify the number of WT/control 
cells. At d7, tdTomato positive enteroid colonies were counted with the Cytation3. 
 
Inhibiting Wnt Signaling in TOP-tdT/PLAGL2 O/E Enteroids 
 Ileum enteroids transfected with BII-ChPt-PLAGL2 or BII-ChPtG-EGFP and the TOP-tdT reporter were 
plated in 24 well plates and treated with 2 !M IWP-2 or vehicle (0.1% DMSO), in triplicate. Fluorescent and bright-
field images were taken every 24 hours with the Cytation3, and medium was changed, with fresh IWP-2/DMSO, 
every 48 hours. In separate experiments enteroids were collected at 48 hours for RNA extraction (Trizol, Thermo 
Fisher Scientific) and RT-PCR for Ascl2, Lgr5, Cd44, Axin2, and Ets2. For examining effects on enteroid survival, 
IWP-2 treatment was continued for a total of 6 days, 48 hours after the complete disappearance of TOP-tdT 
fluorescence. Remaining dead/dying enteroids were then mechanically dissociated and re-plated in 12-well plates 
and fresh ENR medium added to gauge enteroid recovery. After 2 weeks of recovery in ENR, enteroids were 
imaged with the Cytation3 and colonies counted using Gen5 software. 
 
Western Blots (IB) 
To quantify protein levels by IB, enteroid lysates were prepared using 1x Cell Lysis Buffer (#9803, CST) 
supplemented with 1x protease inhibitor cocktail (P8340, Sigma), 2 mM Na3VO4, and 5 mM sodium pyrophosphate. 
Lysates were run on Biorad pre-cast acrylamide gels and transferred to nylon membranes using the Trans-Blot 
Turbo System (Bio-Rad). After blocking with 5% BSA in Tris-buffered saline and 0.1% Tween-20, IB was 
performed using rabbit anti-HA (#3724, CST) or mouse anti-Tubulin (sc-8035, CST) at a 1:1000 dilution and 
visualized with near-infrared fluorescent conjugated secondary antibodies (1:10,000 dilution) on an Odyssey CLx 
near-infrared fluorescence imaging system (LiCor). 
 
Fluorescent Reporter for Assaying miRNA Effects on the PLAGL2 3’UTR 
 To assay sensitivity of the Let-7 reporter to Let-7, 1x105 DLD1 cells were seeded on 24-well plates in 
quadruplicate and transfected the next day with 400 ng of the BII-BCnDFP vector with the Let-7 sponge (BII-
BCnDFP-L7spo) and 100 ng of pCMV-hyPBase. The miRNA cloned into this vector was either a non-specific or 
Let-7a chimeric shRNA. After 48 hours, Puromycin (5 !g/ml) was added and fluorescence was measured every 24-
48 hours using a Biotek Cytation3 with Gen5 software. 
 To assay sensitivity of the PLAGL2 3’UTR, this sequence was PCR amplified from normal human 
genomic DNA (gDNA) (primers in Table S1) and sub-cloned into the SacII and MluI restriction sites in the BII-
BCnDFP vector, just 3’ of the dGFP sequence. Mutations in the Let-7 sequences in the PLAGL2 3’UTR was 
performed by site-directed mutagenesis using Q5 DNA polymerase (NEB). Adaptation for use with the Q5 
polymerase entailed dilution of mutagenesis reactions 1:4 with 1x Cutsmart buffer (NEB) prior to a 1 hour digestion 
with 20 units of DpnI. To assay sensitivity of the PLAGL2 3’UTR to Let-7, transfections were performed as above, 
and fluorescence measured after 7 days of Puromycin (5 !g/ml) selection. 
 
Assaying Ascl2 Promoter Activity with a Fluorescent Reporter 
The proximal 1.47 Kb region of the mouse Ascl2 promoter was cloned into the BII-BCA vector at SfiI sites 
(primers listed in Table S1). To test reporter response to PLAGL2 over-expression, 100 ng of pCMV-hyPBase and 
300 ng of the BII-BCA-Ascl2 vector was co-transfected with 100 ng of BII-ChBt (empty) or BII-ChBt-PLAGL2 
vector in DLD1 cells using 1 !l of JetPrime Transfection Reagent according to manufacturer’s instructions. After 48 
hours, cells were selected for 5 days with 10 !g/ml Blasticidin (MilliporeSigma), and fluorescence measured on day 
6. To test reporter response to PLAGL2 knock-down, DLD1 cells were transfected in 6-well plates with 400 ng of 
pCMV-hyPBase, 1400 ng of the BII-BCA-Ascl2 vector, and 200 ng of BII-ChPt empty vector. 48 hours later, cells 
were selected with 5 !g/ml Puromycin for 3 days, then expanded without Puromycin for 3 additional days. Cells 
were then plated in 24-well plates for transfection with 5 pmoles PLAGL2 siRNAs (IDT, Inc.) and 1.5 !l 
Lipofectamine RNAiMAX (ThermoFisher). Fluorescence was read 72 hours later on a Biotek Cytation3 Imaging 
Platform with Gen5 software. 
 
EdU Incorporation Assays in Human Colonoids 
To measure proliferation, organoid cultures were exposed to 10 !M EdU for 1 hour and fixed at room 
temperature in 4% paraformaldehyde (PFA) for 90 minutes. Organoids were then suspended in a pre-warmed 2% 
agar solution (MilliporeSigma), transferred to molds, and incubated in a 50°C oven for 5 minutes to allow organoid 
settling for optimal sectioning. Molds were transferred to 4°C for solidification, then embedded in paraffin and 
sectioned onto microscope slides by the Digestive Diseases Research Core Center (DDRCC) at Washington 
University in St. Louis. The Click-iT™ Plus EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher) was used to 
visualize EdU-positive cells per the manufacturer’s protocol. Nuclei were stained with Hoechst dye (1:2000) for 1 
hour. ProLong™ Diamond Antifade Mountant (Thermo Fisher) and glass coverslip (Fisher Scientific) were added to 
each slide, then cured 24 hours at room temperature. Images were acquired using a Zeiss Axiovert 200 microscope 
and Axiocam MRM camera with an Apotome optical sectioning filter (Carl Zeiss, Jena, Germany). To quantify 
proliferation, the number of EdU-postive and total nuclei were counted as TIFF files in 10-12 frames per clone using 
ImageJ Software.  
 
Mutagenesis of the PLAGL2 gene in DLD1 cells 
For mutagenesis using SRIRACCHA (Wen et al., 2016), 5 x 105 DLD1 cells were plated into one well of a 
6-well plate and transfected the next day with 500 ng pCMV-hyPBase, 1 !g of BII-C3HTK-PLAGL2-T1, and 1 !g 
of BII-C3H2B-PLAGL2-T2 using 5 !l of JetPrime Transfection Reagent. After 48 hours, cells were selected with 5 
!g/ml Puromycin for 7 days. Cells were re-plated (5 x 105 cells/well) and transfected with 1.2 !g of hCas9-D10A 
plasmid (a gift from George Church, Addgene plasmid #41816), 250 ng pBS-U6gRNA-PLAGL2-T1, 250 ng pBS-
U6gRNA-PLAGL2-T2, 400 ng of pBS-PtH, and 400 ng of pBS-PtH2BG using 5 !l of JetPrime Transfection 
Reagent. These vector backbones were previously described (Wen et al., 2017). 24 hours later, cells were split 
between two wells of a 6-well plate, and transfection with CRISPR plasmids was repeated, as above. Cells were then 
selected 48 hours later with hygromycin (600 !g/ml) for 10 days, and individual GFP-positive hygromycin-resistant 
colonies were picked, expanded, and gDNA isolated for genotyping. 
 
mRNA-Seq 
GFP- and PLAGL2-expressing mouse enteroids were homogenized in Trizol and RNA extracted. Two 
samples from each line were taken, at passages #3 and #4, for mRNA-seq. Total RNA (5 !g) was incubated with 1 
!l (2 U) DNase I and 2 !l of SUPERase-In RNase Inhibitor (Thermo Fisher) in a 50 !l reaction for 10 minutes at 
37°C. RNA was purified with the RNeasy Mini RNA Extraction Kit (Qiagen) and eluted with 15 !l nuclease-free 
ddH2O. Concentrations were determined with the Qubit RNA BR Assay Kit (Thermo Fisher). Samples were 
submitted for mRNA-seq to the Washington University GTAC for ribosomal RNA depletion (with Ribo-Zero rRNA 
Removal Kit, Illumina), sample preparation, and high throughput Illumina deep sequencing. Data analysis by GTAC 
is provided as follows: reads are trimmed, selected for high-quality (PHRED score > 25), aligned to the genome 
using bowtie2 (Langmead, Trapnell et al. 2009), and expression based on RPKM (reads per kilobase million) was 
evaluated by examining differential transcript levels between PLAGL2- and GFP-expressing enteroids. Genes/exons 
are filtered for just those that are expressed and the results are filtered for just those genes or exons found to be 
differentially expressed. The number of genes down-regulated or up-regulated >2-fold for each PLAGL2-expressing 
clone is indicated. GSEA (Figure 3) used a gene set consisting of 600 transcripts up-regulated >3-fold in PLAGL2 
#2 enteroids, and up-regulated >1.05-fold in PLAGL2 #1 enteroids, relative to GFP-TG enteroids. The dataset for 
comparison to this gene set is a ranked list of 3,566 transcripts from Lgr5-EGFP-sorted IESCs selected for up-
regulation or down-regulation, relative to Lgr5-EGFPLOW cells (p<0.05) from a published dataset (Munoz, Stange et 
al. 2012) 
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